Michel Streuli
Chief Executive Officer at Foundery Innovations, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Max Krummel | M | - |
Foundery Innovations, Inc.
 Foundery Innovations, Inc. BiotechnologyHealth Technology Foundery Innovations, Inc. develops transformative immunotherapies for immune-based diseases. The private company is based in San Francisco, CA. Foundery Innovations was founded in 2021 by Michel Streuli, Venkataraman Sriram, Max Krummel. Michel Streuli has been the CEO since 2021. | 3 years |
| Alicia Levey | M | - |
Pionyr Immunotherapeutics, Inc.
 Pionyr Immunotherapeutics, Inc. BiotechnologyHealth Technology Pionyr Immunotherapeutics, Inc. develops cancer immunotherapies. It targets the tumor microenvironment to enhance the body?s antitumor immunity. The company was founded by Max Krummel and Sachdev Sidhu in 2015 and is headquartered in San Francisco, CA. | 5 years |
| Venkataraman Sriram | M | - |
Foundery Innovations, Inc.
Foundery Innovations, Inc. BiotechnologyHealth Technology Foundery Innovations, Inc. develops transformative immunotherapies for immune-based diseases. The private company is based in San Francisco, CA. Foundery Innovations was founded in 2021 by Michel Streuli, Venkataraman Sriram, Max Krummel. Michel Streuli has been the CEO since 2021. | 3 years |
| Elizabeth Edmiston | M | - |
Foundery Innovations, Inc.
Foundery Innovations, Inc. BiotechnologyHealth Technology Foundery Innovations, Inc. develops transformative immunotherapies for immune-based diseases. The private company is based in San Francisco, CA. Foundery Innovations was founded in 2021 by Michel Streuli, Venkataraman Sriram, Max Krummel. Michel Streuli has been the CEO since 2021. | 2 years |
| Andrea Thaddaus Vasella | M | 81 |
University of Zurich
| 43 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stephan Eschmann | M | - |
University of Zurich
| 12 years |
| Marc Bär | M | - |
University of Zurich
| 4 years |
| Markus Dennler | M | 68 |
University of Zurich
| 5 years |
| Hans Wehrli | M | 71 |
University of Zurich
| 7 years |
| Gabriela Maria Payer | M | 61 |
University of Zurich
| 7 years |
| Reto Francioni | M | 68 |
University of Zurich
| 6 years |
| Karl Hofstetter | M | 68 |
University of Zurich
| 3 years |
| Markus Vischer | M | 64 |
University of Zurich
| - |
| Jan A. Bielinski | M | 70 |
University of Zurich
| 6 years |
| Christoph Lengwiler | M | 65 |
University of Zurich
| 6 years |
| Christian Camenzind | M | 64 |
University of Zurich
| 6 years |
| Tobias Guldimann | M | 62 |
University of Zurich
| 4 years |
| Ivo Furrer | M | 67 |
University of Zurich
| 6 years |
| Beat Bernet | M | 69 |
University of Zurich
| 3 years |
| Albrecht Langhart | M | 63 |
University of Zurich
| 3 years |
| Beat Stocker | M | - |
University of Zurich
| 4 years |
| Leonard Reyno | M | 62 |
Pionyr Immunotherapeutics, Inc.
Pionyr Immunotherapeutics, Inc. BiotechnologyHealth Technology Pionyr Immunotherapeutics, Inc. develops cancer immunotherapies. It targets the tumor microenvironment to enhance the body?s antitumor immunity. The company was founded by Max Krummel and Sachdev Sidhu in 2015 and is headquartered in San Francisco, CA. | - |
| Rudolf Marty | M | 75 |
University of Zurich
| 10 years |
| Markus Isenrich | M | 71 |
University of Zurich
| 3 years |
| Laurent Chaix | M | - |
University of Zurich
| 4 years |
| Jürg Sturzenegger | M | 63 |
University of Zurich
| 6 years |
| Andreas Kleeb | M | 61 |
University of Zurich
| 5 years |
| Urs Mäder | M | 68 |
University of Zurich
| 4 years |
| Georg Wohlwend | M | 61 |
University of Zurich
| 7 years |
| Adrian Rüesch | M | 70 |
University of Zurich
| 3 years |
| Markus Schnurrenberger | M | - |
University of Zurich
| 5 years |
| Carol Gallagher | M | 59 |
Pionyr Immunotherapeutics, Inc.
Pionyr Immunotherapeutics, Inc. BiotechnologyHealth Technology Pionyr Immunotherapeutics, Inc. develops cancer immunotherapies. It targets the tumor microenvironment to enhance the body?s antitumor immunity. The company was founded by Max Krummel and Sachdev Sidhu in 2015 and is headquartered in San Francisco, CA. | - |
| Hanspeter Kaspar | M | 62 |
University of Zurich
| 3 years |
| Schlumpf Widmer-Schlumpf | F | 68 |
University of Zurich
| 4 years |
| Markus Heusler | M | 65 |
University of Zurich
| 4 years |
| Thomas Gottstein | M | 60 |
University of Zurich
| 4 years |
| Erich Bohli | M | 74 |
University of Zurich
| 3 years |
| Rudolf Heinrich Escher | M | 67 |
University of Zurich
| 4 years |
| Ralph Mogicato | M | 61 |
University of Zurich
| 3 years |
| Markus Rudolf Neuhaus | M | 66 |
University of Zurich
| 3 years |
| Arjun Goyal | M | - |
Pionyr Immunotherapeutics, Inc.
Pionyr Immunotherapeutics, Inc. BiotechnologyHealth Technology Pionyr Immunotherapeutics, Inc. develops cancer immunotherapies. It targets the tumor microenvironment to enhance the body?s antitumor immunity. The company was founded by Max Krummel and Sachdev Sidhu in 2015 and is headquartered in San Francisco, CA. | - |
| Alexander Vögele | M | 63 |
University of Zurich
| 3 years |
| Reto A. Garzetti | M | 64 |
University of Zurich
| 2 years |
| Walter Locher | M | 69 |
University of Zurich
| 3 years |
| Ingrid Deltenre | F | 64 |
University of Zurich
| 7 years |
| Stefan Breitenstein | M | 67 |
University of Zurich
| 4 years |
| Patrizia Holenstein | M | 67 |
University of Zurich
| 4 years |
| Patrick K. Oesch | M | 66 |
University of Zurich
| 3 years |
| Peter Karlheinz Beck | M | - |
University of Zurich
| 4 years |
| Paul Schneider | M | 69 |
University of Zurich
| 1 years |
| Andreas Casutt | M | 61 |
University of Zurich
| 3 years |
| Stephan Naef | M | 62 |
University of Zurich
| 4 years |
| Daniel Girsberger | M | 64 |
University of Zurich
| 3 years |
| Stephen Rietiker | M | 67 |
University of Zurich
| 3 years |
| Rodolfo Straub | M | - |
University of Zurich
| 3 years |
| Krzysztof Opawski | M | 74 |
University of Zurich
| 1 years |
| Jakob Höhn | M | 64 |
University of Zurich
| 3 years |
| Riet Cadonau | M | 63 |
University of Zurich
| 2 years |
| Tom F. Clausen | M | - |
University of Zurich
| 4 years |
| Christoph Schmid | M | 70 |
University of Zurich
| 3 years |
| Andreas R. Spahni | M | 66 |
University of Zurich
| 4 years |
| Daniel Obrecht | M | 69 |
University of Zurich
| 3 years |
| Dieter A. Enkelmann | M | 65 |
University of Zurich
| 3 years |
| Thomas Knöpfel | M | 73 |
University of Zurich
| 3 years |
| David P. Frick | M | 59 |
University of Zurich
| 5 years |
| Renato Fassbind | M | 69 |
University of Zurich
| 3 years |
| Urs Rohner | M | 65 |
University of Zurich
| 3 years |
| Thomas Rudolf Eichler | M | 69 |
University of Zurich
| 3 years |
| Rolf P. Jetzer | M | 73 |
University of Zurich
| - |
| Markus K. Christen | M | - |
University of Zurich
| 3 years |
| Rudolf Wehrli | M | 75 |
University of Zurich
| 2 years |
| Bjoern Bajan | M | 64 |
University of Zurich
| 4 years |
| Guido Fürer | M | 61 |
University of Zurich
| 1 years |
| Martin M. Naville | M | 65 |
University of Zurich
| 5 years |
| Thomas Wetzel | M | 67 |
University of Zurich
| 3 years |
| Daniel Sigg | M | 67 |
University of Zurich
| 3 years |
| Ralph Max Büchi | M | 67 |
University of Zurich
| 4 years |
| Slawomir Lachowski | M | 66 |
University of Zurich
| 1 years |
| Klaus Kühborth | M | 68 |
University of Zurich
| 4 years |
| Markus Meier | M | 59 |
University of Zurich
| 4 years |
| Peter Schaub | M | 63 |
University of Zurich
| 3 years |
| Felix R. Ehrat | M | 67 |
University of Zurich
| 3 years |
| Gaudenz F. Domenig | M | 68 |
University of Zurich
| 2 years |
| Rudolf W. Fischer | M | 72 |
University of Zurich
| 3 years |
| Jörg Walther | M | 63 |
University of Zurich
| 3 years |
| Jörg Zulauf | M | 66 |
University of Zurich
| 3 years |
| Peter Ilg | M | 58 |
University of Zurich
| 4 years |
| Rudolf Huber | M | 68 |
University of Zurich
| 6 years |
| René Häusler | M | 69 |
University of Zurich
| 1 years |
| Dieter Spälti | M | 63 |
University of Zurich
| 3 years |
| Mike Ellis | M | - |
Pionyr Immunotherapeutics, Inc.
Pionyr Immunotherapeutics, Inc. BiotechnologyHealth Technology Pionyr Immunotherapeutics, Inc. develops cancer immunotherapies. It targets the tumor microenvironment to enhance the body?s antitumor immunity. The company was founded by Max Krummel and Sachdev Sidhu in 2015 and is headquartered in San Francisco, CA. | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Switzerland | 83 | 91.21% |
| United States | 8 | 8.79% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Michel Streuli
- Personal Network
